We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-19.64%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$240M
AUM Growth
-$51.7M
Cap. Flow
+$25.2M
Cap. Flow %
10.52%
Top 10 Hldgs %
50.22%
Holding
91
New
10
Increased
29
Reduced
12
Closed
11

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$6.75M
2
CGEN icon
Compugen
CGEN
+$4.71M
3
AGTC
Applied Genetic Technologies Corporation
AGTC
+$4.22M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$3.78M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$3.7M

Top Sells

Rank Stock Value
1
ARQL
Arqule Inc
ARQL
+$9.94M
2
CYTK icon
Cytokinetics
CYTK
+$4.44M
3
YARW
Yarrow Bioscience, Inc. Common Stock
YARW
+$3.7M
4
ATRC icon
AtriCure
ATRC
+$2.84M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$2.65M

Sector Composition

Rank Sector Weight
1 Healthcare 91.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OTIC
51
DELISTED
Otonomy, Inc.
OTIC
$924K 0.39%
469,135
– –
PRVL
52
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$914K 0.38%
75,000
– –
MDGL icon
53
Madrigal Pharmaceuticals
MDGL
$11.8B
$908K 0.38%
13,600
– –
MGNX icon
54
MacroGenics
MGNX
$257M
$873K 0.36%
150,000
– –
SYBX
55
DELISTED
Synlogic
SYBX
$861K 0.36%
33,382
– –
CTMX icon
56
CytomX Therapeutics
CTMX
$754M
$767K 0.32%
100,000
– –
NXTC icon
57
NextCure
NXTC
$26.7M
$741K 0.31%
1,667
– –
ARCT icon
58
Arcturus Therapeutics
ARCT
$211M
$715K 0.3%
52,586
-121,328
-70% -$1.55M
TCRR
59
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$610K 0.25%
+78,786
New +$964K
ARGX icon
60
argenx
ARGX
$54.1B
$589K 0.25%
4,471
-1,600
-26% -$234K
MORF
61
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$543K 0.23%
37,000
– –
MASI
62
DELISTED
Masimo
MASI
$531K 0.22%
3,000
– –
ASMB icon
63
Assembly Biosciences
ASMB
$529M
$528K 0.22%
2,964
– –
GMDA
64
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$449K 0.19%
148,781
– –
KRTX
65
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$449K 0.19%
+6,231
New +$533K
STRO icon
66
Sutro Biopharma
STRO
$421M
$408K 0.17%
4,000
– –
XCUR icon
67
Exicure
XCUR
$8.57M
$407K 0.17%
1,833
– –
SPRO icon
68
Spero Therapeutics
SPRO
$73M
$389K 0.16%
+48,103
New +$424K
RCUS icon
69
Arcus Biosciences
RCUS
$3.64B
$386K 0.16%
+27,798
New +$346K
ELOX
70
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
$375K 0.16%
4,787
-359
-7% -$58.5K
GRTS
71
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$291K 0.12%
50,000
– –
RDUS
72
DELISTED
Radius Health, Inc.
RDUS
$286K 0.12%
22,000
– –
RIGL icon
73
Rigel Pharmaceuticals
RIGL
$750M
$246K 0.1%
15,770
– –
LRMR icon
74
Larimar Therapeutics
LRMR
$432M
$235K 0.1%
25,458
– –
BTAI icon
75
BioXcel Therapeutics
BTAI
$27.8M
$103K 0.04%
+288
New +$104K
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return
BCM
Beck Capital Management Austin, Texas $437M AUM 59.35% 1-Year Est. Return

DAFNA Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, DAFNA Capital Management held 91 positions worth $240M, down 18% from $291M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

DAFNA Capital Management deployed $25.2M of net new capital in Q1 2020, opening 10 new positions and adding to 29 existing holdings. Its largest new stake was Compugen: 600,000 shares worth $4.36M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 92% a quarter earlier.

On the sell side, the largest reduction was AtriCure, an estimated $2.84M trimmed.

  • DAFNA Capital Management's largest Q1 2020 buy was Compugen: 600,000 shares worth $4.36M.
  • DAFNA Capital Management added most to Blueprint Medicines in Q1 2020, an estimated $6.75M increase.
  • DAFNA Capital Management's biggest Q1 2020 reduction was AtriCure, cutting an estimated $2.84M.
  • DAFNA Capital Management fully exited Arqule Inc in Q1 2020, selling an estimated $9.94M.
  • DAFNA Capital Management's ten largest holdings make up 50% of its $240M portfolio in Q1 2020.
  • DAFNA Capital Management opened 10 new positions and closed 11 in Q1 2020.
  • DAFNA Capital Management's portfolio value fell 18% quarter-over-quarter to $240M.

Based on DAFNA Capital Management's 13F filing for Q1 2020, filed 15 May 2020.